Stock Scorecard
Stock Summary for Krystal Biotech Inc (KRYS) - $143.08 as of 7/4/2025 1:29:28 AM EST
Total Score
17 out of 30
Safety Score
61 out of 100
Currently on the following lists
None
Tim's Recommendation
Possible Buy
Growth List Algorithm Criteria for KRYS
| Positive Quarterly and Annual earnings growth | |
| P/E ratio less than Industry P/E Ratio | |
| P/E ratio less than Sector P/E Ratio | |
| P/E ratio that is half the Annual earnings growth rate (or less) | |
| Positive net cash position the past year and most recent quarter | |
| Equity to debt ratio greater than 0.75 for past year and most recent quarter | |
| Positive net income past year and 12 trailing months | |
| Free cash flow ratio greater than 0 and less than 10 |
Small Cap List Algorithm Criteria for KRYS
| Revenue growing by at least 20% average per year over the last 5 years | |
| Market Capitalization under 2 billion | |
| Price to Sales (P/S) ratio 12 trailing months less than Industry P/S ratio twelve trailing months | |
| Price to Sales (P/S) ratio 12 trailing months less than Sector P/S ratio twelve trailing months | |
| Net Income past year > Net Income prior year OR Net Income 12 trailing months > Net Income prior year OR Net Income 12 trailing months > Net Income past year |
Dividend List Algorithm Criteria for KRYS
| Declared an ex-dividend date | |
| Forward annual dividend rate greater than 2 | |
| Positive net cash position the past year and most recent quarter | |
| Equity to debt ratio greater than 0.75 for past year and most recent quarter | |
| Current ratio most recent quarter greater than 2 | |
| Cash Flow per Share greater than Trailing Dividend Rate |
Bonus Criteria for KRYS
| P/E ratio less than five-year Average P/E ratio | |
| Last Price to 52 Week Low Ratio Less Than 1 | |
| Total Cash Per Share > Last Day Price | |
| P/S Ratio < 1 | |
| P/B Ratio < 1 |
Safety Rating Criteria for KRYS (61 out of 100)
| Stock Price Rating (Max of 10) | 10 |
| Historical Stock Price Rating (Max of 10) | 9 |
| Stock Price Trend (Max of 10) | 10 |
| Book Value (Max of 10) | 8 |
| Book Value to Price (Max of 10) | 0 |
| Analyst Buy Ratings (Max of 5) | 5 |
| Analyst Strong Buy Ratings (Max of 5) | 4 |
| Dividend Yield Percentage (Max of 10) | 0 |
| Operating Margin (Max of 10) | 6 |
| Trading Volume (Max of 10) | 4 |
| Price to Earnings (Max of 10) | 5 |
| Geopolitical Risk Adjustment (Always 0 for USA or a Negative Number for Non-USA) | 0 |
Latest News for for KRYS
Financial Details for KRYS
Company Overview |
|
|---|---|
| Ticker | KRYS |
| Company Name | Krystal Biotech Inc |
| Country | USA |
| Description | Krystal Biotech, Inc., a clinical-stage biotechnology company, is dedicated to the field of redosable gene therapy to treat serious rare diseases in the United States. The company is headquartered in Pittsburgh, Pennsylvania. |
| Sector Name | LIFE SCIENCES |
| Industry Name | BIOLOGICAL PRODUCTS, (NO DISGNOSTIC SUBSTANCES) |
| Most Recent Quarter | 3/31/2025 |
| Next Earnings Date | N/A |
Stock Price History |
|
| Last Day Price | 143.08 |
| Price 4 Years Ago | 69.95 |
| Last Day Price Updated | 7/4/2025 1:29:28 AM EST |
| Last Day Volume | 168,281 |
| Average Daily Volume | 362,264 |
| 52-Week High | 219.34 |
| 52-Week Low | 122.80 |
| Last Price to 52 Week Low | 16.51% |
Valuation Measures |
|
| Trailing PE | 33.34 |
| Industry PE | 58.65 |
| Sector PE | 40.90 |
| 5-Year Average PE | 18.04 |
| Free Cash Flow Ratio | 13.40 |
| Industry Free Cash Flow Ratio | 19.40 |
| Sector Free Cash Flow Ratio | 32.91 |
| Current Ratio Most Recent Quarter | 9.65 |
| Total Cash Per Share | 10.68 |
| Book Value Per Share Most Recent Quarter | 34.07 |
| Price to Book Ratio | 4.08 |
| Industry Price to Book Ratio | 18.75 |
| Sector Price to Book Ratio | 30.76 |
| Price to Sales Ratio Twelve Trailing Months | 12.05 |
| Industry Price to Sales Ratio Twelve Trailing Months | 48.40 |
| Sector Price to Sales Ratio Twelve Trailing Months | 35.60 |
| Analyst Buy Ratings | 8 |
| Analyst Strong Buy Ratings | 2 |
Share Statistics |
|
| Total Shares Outstanding | 28,898,700 |
| Market Capitalization | 4,134,825,996 |
| Institutional Ownership | 104.11% |
Dividends |
|
| Ex-Dividend Date | N/A |
| Previous Dividend Amount | 0.0000 |
| Current Dividend Amount | 0.0000 |
| Total Years Dividend Increasing | N/A |
| Trailing Annual Dividend Rate | 0.00 |
| Trailing Annual Dividend Yield | 0.00% |
| Forward Annual Dividend Rate | 0.00 |
| Forward Annual Dividend Yield | 0.00% |
| 5-Year Dividend Payments Count | 0 |
| 3-Year Average Dividend Yield | 0.00% |
| 5-Year Average Dividend Yield | 0.00% |
| 1-Year Dividend Growth Rate Percentage | 0.00% |
| 3-Year Dividend Growth Rate Percentage | 0.00% |
| 5-Year Dividend Growth Rate Percentage | 0.00% |
| All-Time Dividend Growth Rate Percentage | 0.00% |
| Dividend Payout Ratio | N/A |
Income Statement |
|
| Quarterly Earnings Growth YOY | 3,900.00% |
| Annual Earnings Growth | 715.58% |
| Reported EPS 12 Trailing Months | 4.17 |
| Reported EPS Past Year | 1.20 |
| Reported EPS Prior Year | 3.00 |
| Net Income Twelve Trailing Months | 123,960,000 |
| Net Income Past Year | 89,159,000 |
| Net Income Prior Year | 10,932,000 |
| Quarterly Revenue Growth YOY | 94.90% |
| 5-Year Revenue Growth | 0.00% |
| Operating Margin Twelve Trailing Months | 41.00% |
Balance Sheet |
|
| Total Cash Most Recent Quarter | 308,770,000 |
| Total Cash Past Year | 344,865,000 |
| Total Cash Prior Year | 358,328,000 |
| Net Cash Position Most Recent Quarter | 308,770,000 |
| Net Cash Position Past Year | 344,865,000 |
| Long Term Debt Past Year | 0 |
| Long Term Debt Prior Year | 0 |
| Total Debt Most Recent Quarter | 0 |
| Equity to Debt Ratio Past Year | 1.00 |
| Equity to Debt Ratio Most Recent Quarter | 1.00 |
| Total Stockholder Equity Past Year | 946,380,000 |
| Total Stockholder Equity Prior Year | 778,641,000 |
| Total Stockholder Equity Most Recent Quarter | 984,674,000 |
Free Cash Flow |
|
| Free Cash Flow Twelve Trailing Months | 129,319,000 |
| Free Cash Flow Per Share Twelve Trailing Months | 4.47 |
| Free Cash Flow Past Year | 119,182,000 |
| Free Cash Flow Prior Year | -100,603,000 |
Options |
|
| Put/Call Ratio | 0.00 |
| Has Options | Options Chain |
| Liquidity Rating | |
Technical Analysis |
|
| Yahoo Finance Chart | Yahoo Finance Chart |
| MACD | 0.53 |
| MACD Signal | -1.04 |
| 20-Day Bollinger Lower Band | 111.66 |
| 20-Day Bollinger Middle Band | 156.66 |
| 20-Day Bollinger Upper Band | 201.66 |
| Beta | 0.66 |
| RSI | 51.49 |
| 50-Day SMA | 169.59 |
| 150-Day SMA | 131.39 |
| 200-Day SMA | 114.28 |
System |
|
| Modified | 7/3/2025 3:38:48 AM EST |